---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-107471"
form_type: "8-K"
ticker: "DWTX"
cik: "0001818844"
company_name: "Dogwood Therapeutics, Inc."
filed_at: "2025-11-06T23:59:59+00:00"
generated_at: "2026-05-16T23:56:59.535105+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Dogwood Therapeutics Q3 2025 net loss $15.7M; cash runway through Q1 2026

## Summary
- Net loss per share of $8.20 vs. $2.05 in Q3 2024; R&D expenses surged to $14.5M from $0.5M.
- 100 patients enrolled, 80 completed in Halneuron Phase 2b trial; interim analysis on track for Q4 2025.
- Secured exclusive worldwide royalty-free license to develop SP16 for cancer-related pain via all-stock transaction.
- Cash and equivalents of $10.1M expected to fund operations into Q1 2026.
- SP16 Phase 1b study fully funded by National Cancer Institute; FDA feedback anticipated.

## SEC filing metadata
- accession: 0001104659-25-107471
- form_type: 8-K
- ticker: DWTX
- cik: 0001818844
- company_name: Dogwood Therapeutics, Inc.
- filed_at: 2025-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818844/000110465925107471/0001104659-25-107471-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818844/000110465925107471/dwtx-20251106x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-107471
- JSON: https://secwatch.observer/filing/0001104659-25-107471.json
- Plain text: https://secwatch.observer/filing/0001104659-25-107471.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.